Dannon class-action suit
This article was originally published in The Tan Sheet
Executive Summary
Class-action lawsuit against yogurt-maker Dannon alleges the firm makes false advertising claims for probiotic-containing products Activia and DanActive. Filed Jan. 23 in a Los Angeles federal court, the suit alleges Dannon's claims that probiotics help regulate digestion and boost immunity lack scientific substantiation and are therefore false. In a Jan. 24 press release, the White Plains, N.Y.-based firm says it "strongly disagrees with the allegations in the lawsuit" and is reviewing the case. In addition, the firm adds: "All of Dannon's claims for Activia and DanActive are completely supported by peer-reviewed science and are in accordance with all laws and regulations. Dannon's advertising has always been and will continue to be absolutely truthful, and Dannon will vigorously challenge this lawsuit." In 2006 the National Advertising Division determined claims for Activia were substantiated (1"The Tan Sheet" Aug. 7, 2006, p. 13)...
You may also be interested in...
Dannon's DanActive And Activia Not Immune To Health Claim Scrutiny
A class-action lawsuit against Dannon, resulting in a $35 million settlement, could open the door to additional "nuisance" suits over functional food claims, one food and drug attorney says
Dannon’s “Naturally Regulates Digestive Tract” Claim Reviewed By NAD
A television ad for Dannon Activia yogurt should clarify that the product's benefits apply to bloating and irregularity, as opposed to the chronic condition of constipation, according to a recent ruling by the National Advertising Division
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.